TGFB1 and neoplasm: While all treatment groups receiving either ZOL and IFO and/or γδ T cells showed improved survival over the untreated control mice, only the TGF-β combined treatment group demonstrated a sustained reduction in tumor burden and a statistically significant survival benefit compared to all other groups.